Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT05661552

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05661552
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05661552. Randomized; no masking; primary purpose treatment. Start 2022-12-01 (actual); primary completion 2025-02-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
Acronym
C-STAR
Condition
Low-Density-Lipoprotein-Type [LDL (LDL cholesterol)] Hyperlipoproteinemia
Intervention (Drug)
Evolocumab 140 MG/ML
Intervention (Drug)
Rosuvastatin 5mg
Intervention (Drug)
Ezetimibe 10mg
Lead sponsor
Yonsei University (class: other)
Collaborator
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct05661552
Content hash
0e575dcf41fed5a1970732512208a51d8d1cc0ac7e1fc0d92f629ec2653ade96